Jeremy Falk, MD
Pulmonary Disease · West Hollywood, CANPI 1114953890
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 93.5% of the total across 4 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Paragonix Technologies, Inc. accounts for 84.0% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2024 at $178 and has fallen 90.9% since, to $16 in 2025. That places this record below the midpoint for pulmonary disease clinicians in CA, where the typical reported total is $1,248.
Across 4 payments — averaging $52.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Paragonix Technologies, Inc.$178
- Intuitive Surgical$16
- Gilead$14
- Ambu Inc.$4
Across 20 payments — averaging $6574.38 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bristol Myers Squibb$55K
- Biogen$51K
- Shire North American Group Inc$22K
- Boehringer Ingelheim$3K
- Takeda Pharmaceuticals U.S.A., Inc.$1K
What the payments were for
- Food & beverage$19894%
- Education$146%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Paragonix Technologies, Inc. | 1 | $178 |
| Intuitive Surgical | 1 | $16 |
| Gilead | 1 | $14 |
| Ambu Inc. | 1 | $4 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SherpaPak$178
- LIVERguard$178
- LUNGguard$178
- BaroGuard$178
- PancreasPak$178
How this compares
$212 in reported general payments places this provider in the 25th percentile of 1,261 pulmonary disease providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 13 | $169,112 |
| JanuviaSitagliptin Phosphate | 27 | $14,031 |
| Valganciclovir Hcl | 46 | $12,932 |
| Breo ElliptaFluticasone/Vilanterol | 12 | $5,017 |
| Azithromycin | 105 | $633 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 23 | $597 |
| Nateglinide | 17 | $451 |
| Pantoprazole Sodium | 71 | $446 |
| Prednisone | 38 | $169 |
| Gabapentin | 24 | $148 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 92 | $119 |
| Montelukast Sodium | 13 | $79 |
| Amlodipine Besylate | 13 | $27 |
| Atorvastatin Calcium | 14 | $22 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in West Hollywood
- Paul NobleWest Hollywood$306K
- Oren FriedmanWest Hollywood$278K
- Tanzira ZamanWest Hollywood$105K
- Samuel LouieSacramento$2.8M
- Shyamsunder SubramanianTracy$1.5M
- Toby MaherLos Angeles$1.3M
- Rajkumar DasguptaPasadena$930K
- Hoang leFountain Valley$814K
- Kevin FussellEncinitas$788K
- Revati ShreeniwasStanford$726K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.